Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial

• Published in: Urology (Ridgewood, N.J.) Vol. 62; no. 1; pp. 121 - 125
• Main Authors: Porst, Hartmut, Padma-Nathan, Harin, Giuliano, François, Anglin, Greg, Varanese, Lucio, Rosen, Raymond
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2003
• Subjects: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Aged; Aged, 80 and over; Carbolines - administration & dosage; Carbolines - pharmacokinetics; Carbolines - therapeutic use; Cyclic Nucleotide Phosphodiesterases, Type 5; Double-Blind Method; Erectile Dysfunction - drug therapy; Half-Life; Humans; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase Inhibitors - administration & dosage; Phosphodiesterase Inhibitors - pharmacokinetics; Phosphodiesterase Inhibitors - therapeutic use; Phosphoric Diester Hydrolases - drug effects; Tadalafil; Time Factors; Treatment Outcome

To examine the therapeutic effects of tadalafil on erectile dysfunction (ED) at 24 and 36 hours after dosing. A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 348 men (mean age 57 years) with ED was conducted in Europe and the United States. Patients were stratifi...